KYTX vs. TECX, KURA, CRGX, HUMA, PHVS, ANNX, KROS, MREO, RAPP, and TRDA
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Tectonic Therapeutic (TECX), Kura Oncology (KURA), CARGO Therapeutics (CRGX), Humacyte (HUMA), Pharvaris (PHVS), Annexon (ANNX), Keros Therapeutics (KROS), Mereo BioPharma Group (MREO), Rapport Therapeutics (RAPP), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry.
Kyverna Therapeutics vs.
Tectonic Therapeutic (NASDAQ:TECX) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.
Kyverna Therapeutics received 3 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 66.67% of users gave Kyverna Therapeutics an outperform vote.
Tectonic Therapeutic currently has a consensus price target of $72.25, suggesting a potential upside of 76.65%. Kyverna Therapeutics has a consensus price target of $25.71, suggesting a potential upside of 672.20%. Given Kyverna Therapeutics' higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Tectonic Therapeutic.
Tectonic Therapeutic has higher earnings, but lower revenue than Kyverna Therapeutics.
Tectonic Therapeutic's return on equity of -35.53% beat Kyverna Therapeutics' return on equity.
62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Kyverna Therapeutics had 29 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 30 mentions for Kyverna Therapeutics and 1 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.86 beat Kyverna Therapeutics' score of 0.17 indicating that Tectonic Therapeutic is being referred to more favorably in the media.
Summary
Tectonic Therapeutic beats Kyverna Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KYTX) was last updated on 1/20/2025 by MarketBeat.com Staff
Free KYTX Stock Alerts